Summary of Product Characteristics
last updated on the eMC:
03/01/2012
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 03/01/2012 and displayed until Current
|
Reasons for adding or updating:
|
-
Change in co-marketing arrangement
|
| Date of revision of text on the SPC: 01-Mar-2010 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
Marketing Agreement with Sanofi Pasteur MSD finishes on 31st December 2011, and Menjugate Kit reverts to the marketing authorisation holder Novartis Vaccines and Diagnostics Limited from 1st January 2012
New contact details:
Medical Information Direct Line: +44 (0)8457 451 500
Medical Information e-mail: service.uk@novartis.com
Medical Information Fax: +44 (0)1517 055 669
|
|
Updated on 07/09/2005 and displayed until 03/01/2012
|
Reasons for adding or updating:
|
-
New SPC for new product
-
SPC Submitted in error
|
|
